BCCIP suppresses tumor initiation but is required for tumor progression

Cancer Research

Volumn 73, Issue 23, 2013, Pages 7122-7133

  Huang, Yi Yuan ^a,b   Dai, Li ^a,c   Gaines, Dakim ^a   Droz Rosario, Roberto ^a   Lu, Huimei ^a   Liu, Jingmei ^a   Shen, Zhiyuan ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PROTEIN PATCHED 1; SONIC HEDGEHOG PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOH1 GENE; BCCIP GENE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; D CYCLIN GENE; DOWN REGULATION; GENE CASSETTE; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GLI1 GENE; MALIGNANT TRANSFORMATION; MEDULLOBLASTOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PTCH1 GENE; SIGNAL TRANSDUCTION; SMO GENE; TUMOR SUPPRESSOR GENE;

EID: 84890282285     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1766     Document Type: Article

References (50)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
2. Shen Z. Genomic instability and cancer: an introduction. J Mol Cell Biol. 2011;3:1-3.
3. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 1997;386:761, 763.
4. Liu J, Yuan Y, Huan J, Shen Z. Inhibition of breast and brain cancer cell growth by BCCIPalpha, an evolutionarily conserved nuclear protein that interacts with BRCA2. Oncogene 2001;20:336-45.
5. Lu H, et al. The BRCA2-interacting protein BCCIP functions in RAD51 and BRCA2 focus formation and homologous recombinational repair. Mol Cell Biol 2005;25:1949-57.
6. Lu H, Yue J, Meng X, Nickoloff JA, Shen Z. BCCIP regulates homologous recombination by distinct domains and suppresses spontaneous DNA damage. Nucleic Acids Res 2007;35:7160-70.
7. Lu H, et al. Essential roles of BCCIP in mouse embryonic development and structural stability of chromosomes. PLoS Genet 2011;7:e1002291.
8. Meng X, Fan J, Shen Z. Roles of BCCIP in chromosome stability and cytokinesis. Oncogene 2007;26:6253-60.
9. Meng X, Liu J, Shen Z. Genomic structure of the human BCCIP gene and its expression in cancer. Gene 2003;302:139-46.
10. Meng X, Liu J, Shen Z. Inhibition of G1 to S cell cycle progression by BCCIP beta. Cell Cycle 2004;3:343-8.
11. Meng X, Lu H, Shen Z. BCCIP functions through p53 to regulate the expression of p21Waf1/Cip1. Cell Cycle 2004;3:1457-62.
12. Meng X, Yue J, Liu Z, Shen Z. Abrogation of the transactivation activity of p53 by BCCIP down-regulation. J Biol Chem 2007;282:1570-6.
13. Fan J, Wray J, Meng X, Shen Z. BCCIP is required for the nuclear localization of the p21 protein. Cell Cycle 2009;8:3019-24.
14. Huang YY, Lu H, Liu S, Droz-Rosario R, Shen Z. Requirement of mouse BCCIP for neural development and progenitor proliferation. PLoS ONE 2012;7:e30638.
15. Mao N, Zhou Q, Kojic M, Perez-Martin J, Holloman WK. Ortholog of BRCA2-interacting protein BCCIP controls morphogenetic responses during DNA replication stress in Ustilago maydis. DNA Repair (Amst) 2007;6:1651-60.
16. Liu J, Lu H, Ohgaki H, Merlo A, Shen Z. Alterations of BCCIP, a BRCA2 interacting protein, in astrocytomas. BMC Cancer 2009;9:268.
17. Roversi G, et al. Identifi cation of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines. Oncogene 2006;25:1571-83.
18. Rewari A, et al. BCCIP as a prognostic marker for radiotherapy of laryngeal cancer. Radiother Oncol 2009;90:183-8.
19. Lee Y, et al. Patched2 modulates tumorigenesis in patched1 heterozygous mice. Cancer Res 2006;66:6964-71.
20. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev 2000;14:994-1004.
21. Zhuo L, et al. hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo. Genesis 2001;31:85-94.
22. Frappart PO, et al. Recurrent genomic alterations characterize medullo-blastoma arising from DNA double-strand break repair deficiency. Proc Natl Acad Sci USA 2009;106:1880-5.
23. Brenner M, Kisseberth WC, Su Y, Besnard F, Messing A. GFAP promoter directs astrocyte-specific expression in transgenic mice. J Neurosci 1994;14:1030-7.
24. Brenner M. Structure and transcriptional regulation of the GFAP gene. Brain Pathol 1994;4:245-57.
25. Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu Rev Neurosci 2001;24:385-428.
26. Zindy F, et al. Genetic alterations in mouse medulloblastomas and generation of tumors de novo from primary cerebellar granule neuron precursors. Cancer Res 2007;67:2676-84.
27. Gilbertson RJ, Ellison DW. The origins of medulloblastoma subtypes. Annu Rev Pathol 2008;3:341-65.
28. Marino S. Medulloblastoma: developmental mechanisms out of control. Trends Mol Med 2005;11:17-22.
29. Gibson P, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 2010;468:1095-9.
30. Stecca B, Ruiz i Altaba A Brain as a paradigm of organ growth: Hedgehog-Gli signaling in neural stem cells and brain tumors. J Neurobiol 2005;64:476-90.
31. Dellovade T, Romer JT, Curran T, Rubin LL. The hedgehog pathway and neurological disorders. Annu Rev Neurosci 2006;29:539-63.
32. Ruiz i Altaba A, Palma V, Dahmane N. Hedgehog-Gli signalling and the growth of the brain. Nat Rev Neurosci 2002;3:24-33.
33. Zurawel RH, et al. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosomes Cancer 2000;27:44-51.
34. Kenney AM, Cole MD, Rowitch DH. Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development 2003;130:15-28.
35. Huard JM, Forster CC, Carter ML, Sicinski P, Ross ME. Cerebellar histogenesis is disturbed in mice lacking cyclin D2. Development 1999;126:1927-35.
36. Pogoriler J, Millen K, Utset M, Du W. Loss of cyclin D1 impairs cerebellar development and suppresses medulloblastoma formation. Development 2006;133:3929-37.
37. Lee Y, et al. A molecular fingerprint for medulloblastoma. Cancer Res 2003;63:5428-37.
38. Castellino RC, et al. Heterozygosity for Pten promotes tumorigenesis in a mouse model of medulloblastoma. PLoS One 2010;5:e10849.
39. Hartmann W, et al. Phosphatidylinositol 3′-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin Cancer Res 2006;12:3019-27.
40. Griffin CA, Hawkins AL, Packer RJ, Rorke LB, Emanuel BS. Chromosome abnormalities in pediatric brain tumors. Cancer Res 1988;48:175-80.
41. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 2000;20:5010-8.
42. Yang Z, et al. Reduced expression of PTEN and increased PTEN phosphorylation at residue Ser380 in gastric cancer tissues: a novel mechanism of PTEN inactivation. Clin Res Hepatol Gastroenterol 2013;37:72-9.
43. Frappart PO, McKinnon PJ. Mouse models of DNA double-strand break repair and neurological disease. DNA Repair (Amst) 2008;7:1051-60.
44. Frappart PO, Lee Y, Lamont J, McKinnon PJ. BRCA2 is required for neurogenesis and suppression of medulloblastoma. EMBO J 2007;26:2732-42.
45. Frappart PO, et al. An essential function for NBS1 in the prevention of ataxia and cerebellar defects. Nat Med 2005;11:538-44.
46. Tronche F, et al. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genet 1999;23:99-103.
47. Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 2010;10:319-31.
48. Monje M, Beachy PA, Fisher PG. Hedgehogs, flies, Wnts and MYCs: the time has come for many things in medulloblastoma. J Clin Oncol 2011;29:1395-8.
49. Northcott PA, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011;29:1408-14.
50. Cho YJ, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011;29:1424-30.